智翔金泰(688443.SH)签订唯康度塔单抗注射液以及斯乐韦米单抗注射液商业化合作协议

Core Viewpoint - The company, Zhixiang Jintai, has entered into exclusive cooperation agreements with Kangzhe Pharmaceutical Holdings and its subsidiary, Tibet Kangzhe Pharmaceutical Development, for the commercialization of two monoclonal antibody injections, GR2001 and GR1801, in various regions [1][2] Group 1: GR2001 Injection Agreement - Tibet Kangzhe will obtain exclusive commercialization rights for GR2001 in mainland China, while RXILIENT will have exclusive licensing rights for the Asia-Pacific region and the Middle East and North Africa, excluding mainland China [1] - The company will receive upfront payments and milestone payments totaling up to approximately 260 million RMB, along with sales revenue from mainland China and supply income based on net sales in the Asia-Pacific region and the Middle East and North Africa [1] - The company will pay promotional service fees to Tibet Kangzhe based on sales revenue in mainland China as per the agreement [1] Group 2: GR1801 Injection Agreement - Tibet Kangzhe will obtain exclusive commercialization rights for GR1801 in mainland China, while RXILIENT will have exclusive licensing rights for the Asia-Pacific region and the Middle East and North Africa, excluding mainland China [2] - The company will receive upfront payments and milestone payments totaling up to approximately 250 million RMB, along with sales revenue from mainland China and supply income based on net sales in the Asia-Pacific region and the Middle East and North Africa [2] - The company will pay promotional service fees to Tibet Kangzhe based on sales revenue in mainland China as per the agreement [2]